Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

15.21 +0.16 (+1.06%)
Streaming Delayed Price Updated: 12:50 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023 ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Regenxbio ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023 ↗
 
Via Benzinga
News headline image
Regenxbio's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations for Regenxbio's Future ↗
 
Via Benzinga
News headline image
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
News headline image
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now? ↗
The company focuses on using its technology for gene-editing therapies. 
Via The Motley Fool
News headline image
Earnings Preview: Regenxbio ↗
 
Via Benzinga
Looking Into Regenxbio's Return On Capital Employed ↗
 
Via Benzinga
5 Analysts Have This to Say About Regenxbio ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Regenxbio ↗
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity ↗
 
Via Benzinga
News headline image
Tesla To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Monday ↗
Citigroup raised the price target for The Manitowoc Company, Inc. (NYSE: MTW) from $11 to $21. Citigroup analyst Timothy Thein maintained a Neutral rating. Manitowoc shares fell 2.4% to $19.09 in... 
Via Benzinga
News headline image
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Regenxbio's Earnings Outlook ↗
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
News headline image
Alphabet To $114? Plus This Analyst Predicts $145 For Disney ↗
B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Regenxbio ↗
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
News headline image
4 Analysts Have This to Say About Regenxbio ↗
  Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Recap: Regenxbio Q3 Earnings ↗
Regenxbio (NASDAQ:RGNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target ↗
 
Via Benzinga
News headline image
Expert Ratings for Regenxbio ↗
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter: 
Via Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2022 ↗
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
News headline image
Regenxbio's Earnings Outlook ↗
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
News headline image
5 Small-Cap S&P Stocks To Buy With The Most Upside ↗
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than... 
Via Benzinga
News headline image
Regenxbio's Return On Capital Employed Overview ↗
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.